COVID-19. Coronavirus infection, unspecified
Conditions
Interventions
Intervention 1: Intervention group: In addition to the essential and standard treatment for COVID-19, one tablet of atorvastatin 20 mg (Abidi pharmaceutical company), once daily will be administered f
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age 18 years or older Diagnosis of COVID-19 by RT PCR test and CT scan of the lung and the opinion of the specialist physician Hospitalization in the intensive care unit Full consent and acceptance of the patient or their legal guardian to recruit in the study Possibility to follow the patient for at least 7 days
Exclusion criteria
Exclusion criteria: Contraindications to the use of atorvastatin include allergic reactions to the drug, active liver disease or persistent and unexplained increase in liver enzymes, pregnancy and lactation, severe hepatic or renal insufficiency (clcr <30 ml / min) Malignancy or underlying immunodeficiency or concomitant use of immunosuppressive drugs Intubated patient under care with mechanical ventilation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical improvement of COVID-19. Timepoint: Day: 1, 3, 7 and 14. Method of measurement: APACHE score, evaluation of vital signs? relevant laboratory and arterial blood gas analysis. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShadi Farsaei
Esfahan University of Medical Sciences
Outcome results
None listed